SBIR/STTR Research Award

2-D Microfluidic Gene Scanner

Award identifier fccb210bc4cc37ed47718df6b52172f25814eb70335b33db695ef76dd733893cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$155,455

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CALIBRANT BIOSYSTEMS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Two-dimensional (2-D) DNA gel electrophores allows DNA fragments to be resolved in two dimensions based on their differences in size and sequence. Apart from nucleotide sequencing, this technique provides the only method with a theoretical sensitivity of virtually 100% for mutation detection. At present, 2-D DNA gel electrophoresis is relatively cost-effective in comparison with other mutation detection techniques, but it is not a high-throughput platform for large-scale DNA analysis. Despite the selectivity and sensitivity of conventional 2-D DNA analysis, this technique as practiced today is a collection of manually intensive and time-consuming tasks, prone to poor reproducibility and quantitative accuracy. To increase throughput and decrease cost, automation and miniaturization are beneficial strategies. The specific aims of our proposed research are to (i) develop a 2-D microfluidic gene scanner employing microfluidic networks in disposable plastic substrates, and (ii) demonstrate the speed and resolving power of the 2-D microfluidic gene scanner using the E. coli and yeast genomes as model systems during the Phase I project. Upon demonstration of the 2-D microfluidic gene scanner for rapid and high resolution DNA analysis, we will integrate the technology with the computerized design of PCR primers which generate a large number of DGGE-optimized target fragments in one single reaction, i.e. a PCR multiplex. Our goal is to develop and commercialize an extensive parallel gene scanner for mutation detection in large human disease genes and exploring human genetic variability in population-based studies. PROPOSED COMMERCIAL APPLICATIONS: The technology to be developed in the proposed research is a new tool for massively parallel, high throughput genome, screening, and rapid and thorough evaluation of genetic mutation. Potential customers for the 2-D gene scanner instrument are widespread, including medical diagnostics and biopharmaceutical companies interested in high speed diagnostics, disease research, gene therapy development, and drug discovery.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.